93 related articles for article (PubMed ID: 21054985)
1. [Impact of S100P expression on clinical outcomes of gastric cancer patients with adjuvant chemotherapy of oxaliplatin and its mechanisms].
Zhao XM; Bai ZG; Ma XM; Zhang ZT; Shi XY
Zhonghua Wai Ke Za Zhi; 2010 Jul; 48(13):1004-8. PubMed ID: 21054985
[TBL] [Abstract][Full Text] [Related]
2. S100P enhances the chemosensitivity of human gastric cancer cell lines.
Zhao X; Bai Z; Wu P; Zhang Z
Cancer Biomark; 2013; 13(1):1-10. PubMed ID: 23736016
[TBL] [Abstract][Full Text] [Related]
3. S100P predicts prognosis and drug resistance in gastric cancer.
Ge F; Wang C; Wang W; Wu B
Int J Biol Markers; 2013 Dec; 28(4):e387-92. PubMed ID: 23722300
[TBL] [Abstract][Full Text] [Related]
4. Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy.
Zhang YY; Gu KS; Wu HY; Yang F; Bu LJ; Zhao CC; Zhang YR
Genet Mol Res; 2015 Dec; 14(4):15921-9. PubMed ID: 26662383
[TBL] [Abstract][Full Text] [Related]
5. S100P contributes to chemosensitivity of human ovarian cancer cell line OVCAR3.
He Z; Gao J; Wang Q; Liu M; Li Y; Li X; Tang H; Zheng J
Oncol Rep; 2008 Aug; 20(2):325-32. PubMed ID: 18636193
[TBL] [Abstract][Full Text] [Related]
6. High mobility group-box 3 overexpression is associated with poor prognosis of resected gastric adenocarcinoma.
Tang HR; Luo XQ; Xu G; Wang Y; Feng ZJ; Xu H; Shi YW; Zhang Q; Wu LG; Xue CQ; Wang CW; Wu CY
World J Gastroenterol; 2012 Dec; 18(48):7319-26. PubMed ID: 23326140
[TBL] [Abstract][Full Text] [Related]
7. Polyene phosphatidylcholine overcomes oxaliplatin resistance in human gastric cancer BGC823 cells.
Zhang H; Song H; Yuan R; Zhang X; Yu H; Zhao Y; Jiang T
Biochem Biophys Res Commun; 2018 Feb; 497(1):108-114. PubMed ID: 29421658
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy.
Shitara K; Chin K; Yoshikawa T; Katai H; Terashima M; Ito S; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Tsujinaka T
Gastric Cancer; 2017 Jan; 20(1):175-181. PubMed ID: 26626800
[TBL] [Abstract][Full Text] [Related]
9. Latexin expression is downregulated in human gastric carcinomas and exhibits tumor suppressor potential.
Li Y; Basang Z; Ding H; Lu Z; Ning T; Wei H; Cai H; Ke Y
BMC Cancer; 2011 Apr; 11():121. PubMed ID: 21466706
[TBL] [Abstract][Full Text] [Related]
10. Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol.
Namikawa T; Maeda H; Kitagawa H; Oba K; Tsuji A; Yoshikawa T; Kobayashi M; Hanazaki K
BMC Cancer; 2018 Feb; 18(1):186. PubMed ID: 29439671
[TBL] [Abstract][Full Text] [Related]
11. A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy.
Qian J; Qian Y; Wang J; Gu B; Pei D; He S; Zhu F; Røe OD; Xu J; Liu L; Gu Y; Guo R; Yin Y; Shu Y; Chen X
Drug Des Devel Ther; 2016; 10():241-58. PubMed ID: 26966350
[TBL] [Abstract][Full Text] [Related]
12.
Sheng WZ; Chen YS; Tu CT; He J; Zhang B; Gao WD
World J Gastroenterol; 2016 Dec; 22(47):10364-10370. PubMed ID: 28058016
[TBL] [Abstract][Full Text] [Related]
13. Clinical and experimental study of oxaliplatin in treating human gastric carcinoma.
Lin WL; Li DG; Chen Q; Lu HM
World J Gastroenterol; 2004 Oct; 10(19):2911-5. PubMed ID: 15334700
[TBL] [Abstract][Full Text] [Related]
14. MDM2 is a useful prognostic biomarker for resectable gastric cancer.
Ye Y; Li X; Yang J; Miao S; Wang S; Chen Y; Xia X; Wu X; Zhang J; Zhou Y; He S; Tan Y; Qiang F; Li G; Røe OD; Zhou J
Cancer Sci; 2013 May; 104(5):590-8. PubMed ID: 23347235
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Noh SH; Park SR; Yang HK; Chung HC; Chung IJ; Kim SW; Kim HH; Choi JH; Kim HK; Yu W; Lee JI; Shin DB; Ji J; Chen JS; Lim Y; Ha S; Bang YJ;
Lancet Oncol; 2014 Nov; 15(12):1389-96. PubMed ID: 25439693
[TBL] [Abstract][Full Text] [Related]
16. S100P is a molecular determinant of E-cadherin function in gastric cancer.
Carneiro P; Moreira AM; Figueiredo J; Barros R; Oliveira P; Fernandes MS; Ferro A; Almeida R; Oliveira C; Carneiro F; Schmitt F; Paredes J; Velho S; Seruca R
Cell Commun Signal; 2019 Nov; 17(1):155. PubMed ID: 31767037
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of S100P by lentiviral-mediated RNAi promotes apoptosis and suppresses the colony-formation ability of gastric cancer cells.
Zhang Q; Hu H; Shi X; Tang W
Oncol Rep; 2014 May; 31(5):2344-50. PubMed ID: 24677114
[TBL] [Abstract][Full Text] [Related]
18. Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy.
Feng D; Leong M; Li T; Chen L; Li T
World J Surg Oncol; 2015 Jan; 13():11. PubMed ID: 25634099
[TBL] [Abstract][Full Text] [Related]
19. Cancer chemotherapy chemosensitivity testing is useful in evaluating the appropriate adjuvant cancer chemotherapy for stages III/IV gastric cancers without peritoneal dissemination.
Kubota T; Egawa T; Otani Y; Furukawa T; Saikawa Y; Yoshida M; Watanabe M; Kumai K; Kitajima M
Anticancer Res; 2003; 23(1B):583-7. PubMed ID: 12680150
[TBL] [Abstract][Full Text] [Related]
20. Elevated nuclear S100P expression is associated with poor survival in early breast cancer patients.
Maciejczyk A; Łacko A; Ekiert M; Jagoda E; Wysocka T; Matkowski R; Hałoń A; Györffy B; Lage H; Surowiak P
Histol Histopathol; 2013 Apr; 28(4):513-24. PubMed ID: 23364898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
